|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-10-7
|
|
pubmed:abstractText |
Malignancies, a well-known complication of immunosuppressive therapy in renal transplant recipients, represent an important cause of long-term morbidity and mortality. One approach to addressing this problem is identifying agents that display antineoplastic properties concomitant with their immunosuppressive effects.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
749-58
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16210961-Adolescent,
pubmed-meshheading:16210961-Adult,
pubmed-meshheading:16210961-Aged,
pubmed-meshheading:16210961-Cyclosporine,
pubmed-meshheading:16210961-Female,
pubmed-meshheading:16210961-Humans,
pubmed-meshheading:16210961-Immunosuppressive Agents,
pubmed-meshheading:16210961-Incidence,
pubmed-meshheading:16210961-Kidney Transplantation,
pubmed-meshheading:16210961-Male,
pubmed-meshheading:16210961-Middle Aged,
pubmed-meshheading:16210961-Neoplasms,
pubmed-meshheading:16210961-Risk Factors,
pubmed-meshheading:16210961-Sirolimus,
pubmed-meshheading:16210961-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.
|
|
pubmed:affiliation |
The University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA. Barry.D.Kahan@uth.tmc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
